4.8 Article

Latency-Associated Degradation of the MRP1 Drug Transporter During Latent Human Cytomegalovirus Infection

Journal

SCIENCE
Volume 340, Issue 6129, Pages 199-202

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1235047

Keywords

-

Funding

  1. Cambridge Institute for Medical Research
  2. Wellcome Trust [093966/Z/10/Z, 084957/Z/08/Z]
  3. Agency for Science, Technology and Research, Singapore
  4. MRC [G0701279]
  5. NIHR Cambridge Biomedical Research Centre
  6. Medical Research Council [G0701279, MR/K021087/1] Funding Source: researchfish
  7. MRC [MR/K021087/1, G0701279] Funding Source: UKRI
  8. Wellcome Trust [084957/Z/08/Z, 093966/Z/10/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

The reactivation of latent human cytomegalovirus (HCMV) infection after transplantation is associated with high morbidity and mortality. In vivo, myeloid cells and their progenitors are an important site of HCMV latency, whose establishment and/or maintenance require expression of the viral transcript UL138. Using stable isotope labeling by amino acids in cell culture-based mass spectrometry, we found a dramatic UL138-mediated loss of cell surface multidrug resistance-associated protein-1 (MRP1) and the reduction of substrate export by this transporter. Latency-associated loss of MRP1 and accumulation of the cytotoxic drug vincristine, an MRP1 substrate, depleted virus from naturally latent CD14(+) and CD34(+) progenitors, all of which are in vivo sites of latency. The UL138-mediated loss of MRP1 provides a marker for detecting latent HCMV infection and a therapeutic target for eliminating latently infected cells before transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available